"The
Report PharmaPoint: Bipolar Disorder - Global Drug Forecast and
Market Analysis to 2024 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Bipolar disorder is a mental
disorder characterized by periods of mania and depression. The
frequency, severity, and pattern of these episodes can vary
considerably over time and between individuals, making bipolar
disorder one of the most challenging psychiatric disorders to manage.
The bipolar disorder market is widely genericized, with additional
key brands expected to face patent or data exclusivity expiries
during the forecast period. The bipolar disorder market size is
anticipated to contract significantly between 2014 and 2024, driven
largely by the generic erosion of Otsukas Abilify, the highest
selling bipolar disorder product in 2014. The uptake of novel
atypical antipsychotic products will be a principal driver of growth
over the forecast period, as these products offer clinical advantages
that will drive strong uptake. However, sales of these agents will be
limited by the continued utilization of established generic products.
There are currently only two products in Phase III development, which
indicates that bipolar disorder will remain a field of high unmet
need during the forecast period.
View Report At
:http://www.marketresearchreports.biz/analysis/725328
Highlights
Key Questions Answered
-
The bipolar disorder market is heavily genericized and many key
players have chosen to deprioritize the indication. In light of this,
what are the current clinical and environmental unmet needs? Will
there be opportunities in this market for drug developers throughout
the forecast period?
-
The current late-stage bipolar disorder pipeline is sparse, with only
two products in Phase III development. What impact will these drugs
have on the market? How will they affect the treatment algorithm for
bipolar disorder? Will these drugs fulfil any of the unmet needs for
bipolar disorder?
-
The management of bipolar disorder patients is challenging and a
large number of variables can impact treatment outcomes. How does the
diagnosis and treatment of bipolar disorder differ amongst the 8MM?
Which treatment options are most commonly prescribed in each market,
and how will prescribing patterns change over the forecast period?
Key Findings
-
The main driver of growth in the bipolar disorder market will be the
uptake of novel atypical antipsychotic products, such as
Otsuka/Lundbecks Abilify Maintena and Allergan/Gedeon
Richter/Mitsubishi Tanabes Vraylar. These agents are forecast to be
the highest selling bipolar disorder products by 2024, accounting for
34.9% of the bipolar disorder market in the 8MM.
-
There are very few products approved for the treatment of major
depressive episodes, despite the fact that patients most commonly
experience this episode type. This unmet need is not expected to be
addressed during the forecast period due to the sparsity of the
late-stage pipeline.
-
The biggest barrier for growth in the bipolar disorder market will be
fierce competition from generic products. This limits market
opportunities for new and existing players, as uptake of novel
pipeline products would be hindered by their premium price point.
-
Considerable opportunity remains for products with superior safety
profiles compared to the currently available drugs. KOLs noted that
EPS and metabolic changes were significant concerns related to the
antipsychotic drugs.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/725328
Scope
-
Overview of bipolar disorder, including epidemiology, etiology,
pathophysiology, symptoms, diagnosis, and treatment guidelines.
-
Annualized bipolar disorder market revenue, annual cost of therapy
and treatment usage pattern data from 2014 and forecast for ten years
to 2024.
-
Key topics covered include market characterization, unmet needs, R&D
and clinical trials assessment, late stage clinical trial analysis
and implications for the bipolar disorder therapeutics market.
-
Pipeline analysis: focus on two late-stage pipeline bipolar disorder
drugs, discussing emerging trends as well as an overview of earlier
phase drugs and a top-line analysis of off-label treatments.
-
Analysis of the current and future market competition in the global
bipolar disorder therapeutics market. Insightful review of the key
industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its
implications.
Reasons to buy
The
report will enable you to -
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally
a list of acquisition targets included in the pipeline product
company list.
-
Develop business strategies by understanding the trends shaping and
driving the global bipolar disorder therapeutics market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
global bipolar disorder therapeutics market in future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analyzing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Track drug sales in the global bipolar disorder therapeutics market
from 2014-2024.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Table
Of Content
1
Table of Contents 12
1.1
List of Tables 17
1.2
List of Figures 24
2
Introduction 26
2.1
Catalyst 26
2.2
Related Reports 27
2.3
Upcoming Related Reports 27
3
Disease Overview 28
3.1
Etiology and Pathophysiology 28
3.1.1
Etiology 28
3.1.2
Pathophysiology 30
3.2
Classification 34
3.3
Symptoms 40
3.4
Prognosis 41
4
Epidemiology 43
4.1
Disease Background 43
4.2
Risk Factors and Comorbidities 43
4.3
Global Trends 45
4.4
Forecast Methodology 47
4.4.1
Sources Used 53
4.4.2
Sources Not Used 56
4.4.3
Forecast Assumptions and Methods 56
4.5
Epidemiological Forecast of Bipolar Disorder (2014-2024) 60
4.5.1
12-Month Total Prevalent Cases of Bipolar Spectrum Disorder 60
4.5.2
12-Month Total Prevalent Cases of Bipolar I 61
4.5.3
12-Month Total Prevalent Cases of Bipolar II 63
4.5.4
12-Month Total Prevalent Cases of Cyclothymic Disorder 65
4.5.5
Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder 67
4.5.6
Age-Specific 12-Month Total Prevalent Cases of Bipolar I 68
4.5.7
Age-Specific 12-Month Total Prevalent Cases of Bipolar II 70
4.5.8
Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder
72
4.5.9
Sex-Specific 12-Month Total Prevalent Cases of Bipolar I 74
4.5.10
Sex-Specific 12-Month Total Prevalent Cases of Bipolar II 76
4.5.11
Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder
78
4.5.12
Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum
Disorder 80
4.6
Discussion 82
4.6.1
Epidemiological Forecast Insight 82
4.6.2
Limitations of the Analysis 83
4.6.3
Strengths of the Analysis 84
5
Disease Management 85
5.1
Diagnosis Overview 85
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment